Aclaris Therapeutics (ACRS) Tops Q3 EPS by 1c
Tweet
Share
E-mailGet Alerts ACRS Hot Sheet
Join SI Premium – FREE
Aclaris Therapeutics (NASDAQ: ACRS) reported Q3 EPS of ($0.12), $0.01 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $3.3 million versus the consensus estimate of $1.36 million.
For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Benchmark Starts Boyd Gaming (BYD) at Buy
- Zebra Technologies debuts CV70 camera at Automate 2026
- ITG targets $2.67 billion valuation in U.S. IPO
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
